CERO vs. PBM, NIVF, PRE, FHLT, AXDX, MEIP, OCX, DMTK, RNXT, and BIVI
Should you be buying CERo Therapeutics stock or one of its competitors? The main competitors of CERo Therapeutics include Psyence Biomedical (PBM), NewGenIvf Group (NIVF), Prenetics Global (PRE), Future Health ESG (FHLT), Accelerate Diagnostics (AXDX), MEI Pharma (MEIP), OncoCyte (OCX), DermTech (DMTK), RenovoRx (RNXT), and BioVie (BIVI). These companies are all part of the "medical" sector.
CERo Therapeutics (NASDAQ:CERO) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, community ranking, media sentiment, analyst recommendations, institutional ownership and risk.
CERo Therapeutics and Psyence Biomedical both received 0 outperform votes by MarketBeat users.
29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are held by institutional investors. 15.8% of CERo Therapeutics shares are held by insiders. Comparatively, 3.6% of Psyence Biomedical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, CERo Therapeutics' average media sentiment score of 0.00 equaled Psyence Biomedical'saverage media sentiment score.
CERo Therapeutics has a beta of -0.08, indicating that its stock price is 108% less volatile than the S&P 500. Comparatively, Psyence Biomedical has a beta of -0.11, indicating that its stock price is 111% less volatile than the S&P 500.
Summary
CERo Therapeutics beats Psyence Biomedical on 2 of the 3 factors compared between the two stocks.
Get CERo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CERo Therapeutics Competitors List
Related Companies and Tools
